Selonsertib (GS-4997) is a selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1), primarily investigated for its potential therapeutic applications in treating diseases characterized by inflammation and fibrosis. It has been studied extensively in clinical trials for conditions such as non-alcoholic steatohepatitis (NASH), a liver disease involving inflammation and scarring common in patients with obesity and diabetes. By inhibiting ASK1, Selonsertib targets pathways involved in cell stress, oxidative stress, and apoptosis, aiming to reduce fibrosis, prevent cell death, and improve liver function.

Additionally, it has been explored for its role in addressing chronic kidney disease, particularly in patients with albuminuria as a sign of kidney damage, and other fibrotic disorders. This offers a potential treatment avenue for patients with limited therapeutic options. Its application in these areas highlights its potential to modulate disease progression and improve outcomes in chronic fibrotic conditions.

While Selonsertib has shown promising results in clinical studies, further research is needed to confirm its long-term safety and efficacy before widespread medical use.